Leukemia treatment based on anti-CD47 and anti-CD20

• Main Authors: AGORAM BILAL, HUANG JIANMIN, WEISSMAN IGOR LEONIDOVICH, MOTT ROBERT L, M. P. ZHAO, TAKIMOTO CHRIS H M
• Format: Patent
• Language: Chinese; English
• Published: 07.06.2022
• Subjects: CHEMISTRY; HUMAN NECESSITIES; HYGIENE; INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES; MEASURING; MEDICAL OR VETERINARY SCIENCE; METALLURGY; ORGANIC CHEMISTRY; PEPTIDES; PHYSICS; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; TESTING

Provided herein are methods of determining eligibility for a subject to receive treatment based on the presence or absence of B cells in the subject, and subsequently treating the eligible subject with an anti-CD47 treatment in combination with an additional agent, such as an anti-CD20 antibody. 本文提供了基于B细胞存在或不存在于受试者中来确定受试者接受治疗的资格，并且随后用抗CD47治疗与附加药剂诸如抗CD20抗体组合来治疗有资格的受试者的方法。